Navigation

Sub Navigation

Innovative Research & Development

Teva has been engaged in innovative research and development for over two decades now. During this period, it has made significant progress, mainly in two therapeutic fields: central nervous system (CNS ) and autoimmune (AI) diseases. Oncology is recently emerging as a potential new area (see Table). These efforts culminated in 2 innovative products introduction into global markets : Copaxone® ( glatiramer acetate) for MS and Azilect® for Parkinson's disease (PD).

Most of the current pipe-line projects are based on research performed in the leading research institutes and start-up companies in Israel. With the acquisition of Ivax at the beginning of 2006, Teva's Innovative pipe-line has been enriched with several new molecules in clinical and pre-clinical stages of development. Attempts have been recently initiated towards licensing-in of promising products from additional sources.

Approved world-wide as a symptomatic treatment for both early patients, as monotherapy, and advanced patients, as adjuncive treatment to levodopa. A Phase IIIb to show effect on disease progression is on-going